Skip to content

Fresenius Medical Care Ventures

Our Purpose: Creating a future worth living for patients. Worldwide. Every day.

At Fresenius Medical Care Ventures, we believe that innovation can pave the way to the future of healthcare.

Guided by our purpose, Fresenius Medical Care Ventures (FMCV) invests in start-ups and early-stage companies in the healthcare sector. Our strategic investments create partnerships to gain access to new technologies and therapy approaches in our core and complementary businesses. Aligned with our strategic priorities, these equity investments and collaborative partnerships assist portfolio companies in navigating the challenging path of bringing innovation to patients. 

FMCV invests across multiple healthcare sectors, including medical devices, pharmaceuticals, digital healthcare, and healthcare services. We invest from seed stage to later stage depending on how companies fit into our corporate objectives. 

Fresenius Medical Care is committed to bringing critical innovation to patients and will employ the breadth of its resources to assist our portfolio companies in achieving their vision. 

Our Portfolio

Albutec is developing and selling an extracorporeal liver support device with CE label.
Status: Active

SafeRide Health takes non-emergency medical transport further with leading technology and a digitized network that gets patients to the right care and the right time.
Status: Active

eGenesis is committed to ending the global organ transplant shortage and transforming the treatment of organ failure.
Status: Active

A digital behavioral health company enabling accurate diagnosis and acuity measurement allowing for optimal interventions.
Status: Acquired

Modulim's mission is to save limbs and improve lives by empowering healthcare teams with microvascular imaging and democratized data insights.
Status: Active

Stimdia Medical is dedicated to developing medical technology which reduces ventilator weaning times.
Status: Active

Vectorious has developed the V-LAP system to enable physician directed heart failure patient’s self management.
Status: Active

Exthera Medical has developed the Seraph 100 microbind affinity blood filter for removing pathogens from the bloodstream.
Status: Divested

Memo Therapeutic’s AG lead program is neutralizing anti-body to treat BK virus infection in Kidney transplant recipients.
Status: Active

The photoactivated vessel-restoring power of Natural VascularScaffolding is designed to create patency without implants.
Status: Active

The Argos cardiac output monitor enables individualized data driven care that aims to prevent complications.
Status: Active

Magenta Medical is developing a miniaturized catheter-mounted axial flow-pump for mechanical circulatory support of the left ventricle.
Status: Active

Medical grade data capture and insights with clinical accuracy physicians can trust. Advanced analytics and data services to enable early detection of adverse vital sign trends. Cost-effective continuous physiologic monitoring with the award-winning BioButton single-use wearable medical devices.
Status: Active

Pioneering the development and manufacture of off-the-shelf, universally implantable, bioengineered human tissue.
Status: Active

Developed an IL-6 inhibitor to treat cardiac inflammation in CVD patients.
Status: Acquired

Stealth Company

Transplant support technology

DocGo is a leading provider of last-mile mobile health services and integrated medical mobility solutions. DocGo’s Mobile Health bridges the gap between telemedicine visits and in-person treatments by fully integrating with industry-leading EHR providers to enable seamless care logistics. Our AI-powered transportation and concierge medical services enable our clinical professionals to facilitate high-quality patient-centered care, helping improve patient outcomes while reducing the total cost of care for our customers.

Our Team / Ventures

Dr. Olaf Schermeier

Chief Executive Officer, Critical Care and Ventures

Dr. Olaf Schermeier took over the position of CEO Critical Care & Ventures in January 2022. He started with Fresenius Medical Care in March 2013 as Chief Officer for Global Research and Development and Member of the Management Board.  Dr. Schermeier has >20 years of experience in the health care industry, among others at Draeger Medical, Biotronik and Charité-hospital. He holds a doctorate degree (PhD) in Computer Science from the Technical University of Berlin, Germany and graduated from the University of Hannover, Germany in Electrical Engineering.

Olaf's Linkedin profile

Albert Wiegman, MBA 

Managing Director
Vice President, Head of Ventures

With over 25 years of experience in venture capital, Mr. Wiegman has directly participated in 50 early-stage venture investments in software, healthcare IT, medical devices and healthcare services. A hands-on board member, he is passionate about investment and value-creation processes combined with a unique blend of strategic and operational expertise.

Albert's Linkedin profile

Andreas Wuepper, PhD, MBA

Managing Director
Director Investments, Europe

Andreas has an educational background in both life science and finance and has more than 25 years of experience in the medical device industry. Andreas is part of the team of Fresenius Medical Ventures since it was established in 2016. In his current role as Managing Director, he has full responsibility for investments across the investment cycle from deal sourcing to deal execution and portfolio management. He currently holds active board roles in Alucent Biomedical and Memo Therapeutics.
Andreas joined Fresenius Medical Care in 1999 and held different managerial positions in product development and portfolio management. Prior to joining Fresenius, he worked for Saxonia Medical GmbH. Andreas holds a PhD in Physical Chemistry from the University of Cologne, Germany, and an MBA from the University of Krems, Austria.

Andreas's Linkedin profile

Adi Shaked

Venture Innovation Manager- Israel

Adi Shaked joined FMCV in June 2020 as Venture Innovation Manager, Israel. Adi is responsible for evaluating investment opportunities in Israel.
Prior to joining FMCV, Adi spent 10 years as Deal Flow Manager at SCP Vitalife and was Marketing Manager at Medtronic Vascular in the U.S. 
Adi brings a strong business development and marketing background in Medical Devices and has a professional passion in making a meaningful impact on people’s lives.

Adi's Linkedin profile

Thomas Spellman

Managing Director
Vice President, Associate General Counsel

Tom is an in-house transactional attorney at Fresenius Medical Care. Tom is the lead attorney for FMC Ventures, as well as supporting M&A and joint venture activity for the US operations of Care Delivery. Tom has been with Fresenius Medical Care since August 2015. Prior to jointing Fresenius Medical Care, Tom spent 6 years at Goodwin LLP, in the Business Law Department. At Goodwin, Tom spent most of his time working on PE and VC M&A transactions, private fund formation and operation, and transactional support for financial institutions.

Tom's Linkedin profile

David Lefebvre

Associate General Counsel, Center of Excellence, Intellectual Property

David Lefebvre is an in-house patent attorney in Fresenius Medical Care’s global IP group.  David is the primary IP support for FMC Ventures and has been with Fresenius Medical Care since August 2019.  Prior to joining Fresenius Medical Care, David spent seven years at Finnegan LLP where his practice focused on client counseling, patent prosecution, portfolio management, post-grant practice, and patent litigation.

David's Linkedin profile

Peter Hennke

Managing Director
Senior Vice President Legal, Head of Center of Excellence, Corporate Governance

Dr. Peter Hennke joined Fresenius Medical Care in 2004, where he is Managing Director of Fresenius Medical Care Ventures GmbH. He is also Senior Vice President of the CoE Corporate Governance of the Global Legal Function. Dr. Hennke studied law at the University of Augsburg and passed his Second State Law Examination in State Examination in Law in Bavaria. He completed his doctorate in the field of stock corporation law and acquired the titles of specialist lawyer for tax law and certified finance expert.

Peter's linkedin profile

Rouven Boch

Managing Director
Head of Finance, Portfolio management, Strategy & M&A    ​
Critical Care & Ventures ​
CEO Unicyte AG (a Fresenius Medical Care company) ​
CFO Xenios AG (a Fresenius Medical Care company) ​
Senior Vice President ​
Care Enablement (CE) ​
Fresenius Medical Care 

Rouven joined Fresenius Medical Care in 2015 as the Vice President of Global Financial Strategy. From 2019 onwards Rouven was serving as the Head of Global Financial Planning & Analysis and acting as the Business Partner for the Group CFO.  In 2022 he took over the Head of Finance role for FME’s business unit Critical Care & Ventures (CC&V) including extended responsibilities leading the business unit’s strategic portfolio management efforts. In addition, Rouven has been appointed as the CEO for Suisse based Unicyte AG (regenerative medicine) by FME Mgt. Board in 2023 and serves as the CFO of Xenios AG.  

Before joining Fresenius Medical Care, Rouven worked for several professional service and consulting firms such as KPMG and Accenture since 2008 focusing on advising and auditing commercial clients and PE firms. 

Rouven Boch pursued the MBA program in HSG, St. Gallen, Switzerland and ESADE, Barcelona, Spain, from 2013 to 2015. Rouven received his Master degree in Business Administration at University of Mannheim, Mannheim, Germany in 2008. August 2023 

Rouven’s Linkedin profile

Our team / Emerging Business

Franklin W. Maddux, MD FACP

Global Chief Medical Officer

Franklin W. Maddux is Global Chief Medical Officer and Member of the Management Board for Fresenius Medical Care, overseeing the delivery of high-quality, value-based care for the world’s most expansive kidney care organization. His distinguished career encompasses more than three decades of experience as a physician, expert nephrologist, technology entrepreneur, and healthcare executive.

Franklin's Linkedin profile

Jan Walter

President, Emerging Businesses

Jan is an experienced global healthcare executive with a unique track record across Pharma, MedTech and Healthcare Services. ​
​Jan led large regional organizations focusing on growth initiatives covering geographical expansions, M&A projects, complex JV structures and manufacturing setups. Jan has a keen eye for strategic growth opportunities, while fostering operational excellence, compliance, and organizational maturity.​
Currently Jan is heading the Emerging Businesses Unit under FMC's Global Medical Office spearheading FMC's startup investment in Regenerative Medicine, Transplant, Genomics and Clinical Research.  

Jan's Linkedin profile

Benjamin Hippen, MD, FASN, FAST

Senior Vice President for Transplantation Medicine and Emerging Capabilities, Global Medical Office

Benjamin Hippen is Senior Vice President and Head of Transplant Medicine and Emerging Capabilities, leading the company’s worldwide efforts to expand access to transplantation. He received his bachelor’s degree in philosophy from Rice University and his medical degree from Baylor College of Medicine, and he completed his fellowship in nephrology and renal transplantation at the University of Alabama at Birmingham.  He is currently a Clinical Professor of Medicine at the University of North Carolina at Chapel Hill School of Medicine. Prior to joining Fresenius Medical Care, Dr. Hippen was a full-time general and transplant nephrologist and physician partner with Metrolina Nephrology Associates, a 38-nephrologist private practice in Charlotte, North Carolina, where he served as medical director of both a large in-center dialysis facility and home therapies unit. He is the author of more than 60 peer-reviewed manuscripts focused on ethics and public policy issues in nephrology and transplantation.

Benjamin's Linkedin profile

Get in touch